Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

VanEck Pharmaceutical ETF (PPH) offers a lower 0.36% expense ratio and 2.0% trailing-12-month dividend yield versus 0.58% and 0.9%, respectively, for Invesco Pharmaceuticals ETF (PJP). PJP outperformed over the past year, returning 41% versus 31% for PPH, while its five-year maximum drawdown was modestly lower at 17.5% versus 20.3%. The article favors PPH for lower-cost, income-oriented investors seeking global exposure and liquidity, while positioning PJP as the stronger-returning U.S.-focused option.

Analysis

The relevant distinction is factor exposure, not the modest fee or distribution differential. PPH is effectively a concentrated large-cap innovation bet: its return path will be dominated by LLY and, to a lesser extent, MRK/NVO. PJP’s near-equal weighting creates materially more exposure to patent-cliff recovery, valuation mean reversion, and pipeline execution at ABBV, GILD, and PFE; its recent outperformance therefore signals that the market has already rewarded the broad pharma catch-up trade rather than simply rerated GLP-1 leaders.

Over the next 1-3 months, relative performance should hinge on GLP-1 prescription, pricing, and capacity data versus upcoming pipeline and capital-return updates from legacy pharma. A renewed growth premium for obesity/metabolic franchises favors PPH, but concentration leaves it vulnerable to any reimbursement restriction, safety signal, or volume deceleration at LLY; a 10% LLY-specific drawdown would mechanically create roughly 200 bps of PPH headwind before correlated peer effects. PJP is the cleaner defensive vehicle if rates rise or growth multiples compress, since its diversified exposure should retain more cash-flow and dividend support.

The contrarian point is that neither ETF is an efficient way to express a high-conviction pharma view at current dispersion: PPH embeds one dominant winner, while PJP dilutes the very valuation-recovery names that could benefit most from successful late-stage readouts. The useful trade is relative and catalyst-driven, not a broad directional pharma allocation. Monitor GLP-1 channel checks, Medicare/commercial reimbursement language, and 2027 guidance revisions; these will matter more than trailing ETF performance.

Key Decisions for Investors

• Initiate a 1-3 month pair trade: long PJP / short PPH in equal dollar amounts if PJP continues to outperform without a corresponding improvement in LLY/NVO obesity-volume data. Target 5-8% relative upside; exit if LLY raises revenue guidance or PJP’s constituent earnings revisions turn negative.
• For growth exposure, own LLY directly rather than PPH where mandate permits; PPH adds meaningful MRK/NVO exposure while retaining LLY concentration. Size for a 15-20% single-name drawdown risk around reimbursement, supply, or safety headlines.
• Use PPH only as a tactical long after a GLP-1-related pullback and independently confirmed prescription/capacity acceleration. Avoid treating its higher distribution yield as a return catalyst; the principal risk remains concentration-driven multiple compression.
• Watch ABBV, GILD, and PFE earnings revisions and pipeline catalysts as confirmation for the PJP leg. If broad legacy-pharma guidance improves while GLP-1 growth expectations normalize, add to PJP/PHP relative exposure; if the reverse occurs, close the pair.